The call will feature overview presentations by KOLs: Dr. Luc Dirix, MD PhD, from the AZ Sint-Augustinus Hospital in Antwerp, Belgium, and Prof. Salah-Eddin Al-Batran, MD, from the Institute of Clinical Research in Frankfurt, Germany. They will discuss their clinical experience with eftilagimod alpha in AIPAC (metastatic breast cancer) and INSIGHT (exploratory investigator-initiated trial) as well as the current treatment landscape and unmet medical needs, specifically in HER2-negative / HR positive metastatic breast cancer.

Listen to a replay of the Immutep “KOL Call on Novel IO Therapy (eftilagimod alpha)” that took place on Wednesday, June 26, 2019

Click here for the "TACTI-002" poster which will be presented at the ASCO 2019

Click here for the "Insight Trial" poster which will be presented at the ASCO 2019

Venue: McCormick Place, Chicago, IL, USA

Conference Day 2: Friday 17th May 2019/ 11.25.a.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Combining a soluble LAG-3 protein with an anti-PD-1 antibody in phase I-II trials

Click here for the Presentation at World Advanced Therapies & Regenerative Medicine Congress & Expo 2019

Venue: Business Design Centre, London, UK

Frédéric Triebel, CSO & CMO of Immutep, will participate in a panel discussion.

Venue: The New York Academy of Sciences, New York, New York, USA

Venue: Maritim Hotel Berlin, Stauffenbergstrasse 26, 10785 Berlin, Germany

The webcast was hosted by Dr. Triebel, Marc Voigt, CEO and Christian Mueller, Director of Clinical Development.

Register: Interested investors can register via a link to the recorded webcast at the following link.

Listen to the related webcast:  Update on Eftilagimod Alpha (IMP321)

Click here for the Presentation related to the webcast

Representatives of the company will be attending the conference

Venue: Georgia World Congress Center, Atlanta, Georgia, USA

Speakers: Chief Scientific Officer & Chief Medical Officer, Dr. Frederic Triebel and Executive Director and Chief Executive Officer (CEO) Marc Voigt

Listen to the webcast and view the presentation "Immutep IMP761 Preclinical Results in Autoimmune Disease"

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Listen to the recorded webcast “Immutep/Marc Voigt (CEO) to Present at Oppenheimer’s 29th Annual Healthcare Conference” from March 19th, 2019

Click here for the Presentation at Oppenheimer's 29th Annual Healthcare Conference (related to webcast)

Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, USA

Mathieu Angin, Phd, Immutep Research Scientist presents an abstract:

“IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases.”

Session name:         DOP Session 1: Advances in IBD pathophysiology

Session date:           07 March 2019

Session time:           17:30 - 18:30

Session hall:             C1 M1

Venue:  Bella Center, Center Blvd. 5, 2300 Copenhagen, Denmark

Day 2 – Tuesday 5th March/ 3.00 p.m.  

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTive Immunotherapies (TACTI): Results of a Phase I trial with metastatic melanoma patients

click here for presentation

Venue:  Grand Hyatt, San Diego, USA

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Venue: SYDNEY InterContinental, 170 Macquarie Street, Sydney; NSW; Australia

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update.

Venue: BRISBANE Hilton, 190 Elizabeth Street, Brisbane City; QLD; Australia

Venue:    San Francisco, California, USA

conference day 1/ 02.00 p.m.

Frédéric Triebel, CSO & CMO of Immutep speaks on the subject:

Two ACTIve Immunotherapies (TACTI): Results of Phase I Trial With Metastatic Melanoma Patients (TACTI-mel) Treated With a Soluble LAG-3 Receptor (LAG-3lg or Eftilagimod Alpha) as an Antigen Presenting (APC) Activator Combined with Pembrollzumab

Venue: The Sofitel Berlin Kurfuerstendamm, Berlin, Germany

Marc Voigt, CEO of Immutep, will present a corporate overview and business update.

Venue: Macquarie Office -  Sydney, Australia

click here for agenda

The company will have presentations at the conference and representatives will be attending.

Venue:    Walter E. Washington Convention Center, 801 Mt Vernon Pl NW, Washington, D.C., DC 20001, USA

Dr. Victoria Atkinson (Principal Investigator TACTI-mel) speaks on the subject:

"Results from a Phase I dose escalation trial (TACTI-mel) with the soluble LAG-3 protein (IMP321, eftilagimod alpha) together with pembrolizumab in unresectable or metastatic melanoma."

Venue: Manchester Central Convention Complex, Manchester, United Kingdom

Representatives of the company will be attending the conference.

Venue:   Messe Munich, Messegelände, 81823 Munich, Germany, www.messe-muenchen.de

Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live and available for replay via the investor relations section of the company’s website at www.immutep.com.

Listen to the webcast “Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference”

Download "Ladenburg 2018 HC Conference Immutep Presentation"

Marc Voigt, CEO of Immutep, will present a corporate overview and business update with one-on-one meetings held throughout the day. 

Venue:  Millenium Broadway Hotel & Conference Center, NY, USA

Press release: click here

Download "Newsmaker Immutep Corporate Presentation"

Listen to the webcast “Immutep Newsmakers Presentation” from September 7th, 2018

 - the largest networking event for life sciences and healthcare industries in the German capital region -

Venue:    Ludwig Erhard Haus, Fasanenstraße 85, Berlin, Germany

Frédéric Triebel speaks on the subject:

“Two ACTIve Immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3Ig or eftilagimod alpha) as an antigen presenting (APC) activator combined with pembrolizumab.”

Frédéric Triebel speaks on the subject:
“LAG-3: the next immune checkpoint after CTLA-4 and PD-1/PDL-1?”

Venue:  bbc (Berlin Congress Center), Alexanderstr. 11, 10178, Berlin, Germany

Venue:  McCormick Place, Chicago, IL, USA

Company presentation by Jay R. Campbell at 9.00am EDT on Monday, April 9^th

Venue:  Essex House, New York, NY, USA